Olanzapine: Nursing Drug Guide, Metabolic Monitoring & NCLEX Review
Olanzapine drives some of the highest atypical-antipsychotic metabolic risk—track fasting glucose, weight, and lipids from day one, watch for hyperglycemia and rapid weight gain, and escalate NMS or orthostatic collapse without attributing every change to psychiatric symptoms alone.
Olanzapine carries a strong metabolic safety profile: labeling links it to hyperglycemia (sometimes extreme, with ketoacidosis or hyperosmolar coma), dyslipidemia, and weight gain—in adult short-term trials patients gained a mean of 2.6 kg versus 0.3 kg loss on placebo, and 22.2% gained ≥7% of baseline weight. Obtain fasting glucose at baseline and periodically; weigh patients on a consistent schedule. Also monitor for orthostatic hypotension, somnolence, and rare neuroleptic malignant syndrome (NMS). Boxed warning: elderly patients with dementia-related psychosis have increased mortality—olanzapine is not approved for that use.
📋 Contents
⚡ Quick facts
💡 Key takeaway
On olanzapine, weigh the patient on schedule, trend fasting glucose and lipids, and teach polydipsia/polyuria warning signs. In short-term adult trials, mean weight gain was 2.6 kg versus 0.3 kg loss on placebo—do not dismiss appetite or belt-size changes as “just psych meds.” Hold and escalate when glucose spikes, symptomatic hyperglycemia appears, or NMS features (fever, rigidity, confusion, autonomic instability) develop.
Most common brand names
Olanzapine is available as standard tablets and orally disintegrating tablets (ODT). Verify formulation on the MAR—dose units and handling differ between solid and ODT products.
Common brands include Zyprexa and Zyprexa Zydis (ODT). Symbyax combines olanzapine with fluoxetine for bipolar depression and treatment-resistant depression per separate labeling—olanzapine monotherapy is not indicated for bipolar depression or treatment-resistant depression.
Why we give it — Indications
Per current U.S. prescribing information, olanzapine oral monotherapy is indicated for schizophrenia and acute manic/mixed episodes of bipolar I disorder. It is not approved for dementia-related psychosis and carries a boxed warning of increased mortality in that population.
| Use | Detail |
|---|---|
| Schizophrenia | Adults and adolescents 13–17 years |
| Bipolar I — mania/mixed | Adults and adolescents 13–17 years; monotherapy or adjunct to lithium or valproate |
| Bipolar depression / TRD | Not olanzapine monotherapy—use olanzapine + fluoxetine (Symbyax) per separate labeling when prescribed |
| Major depressive disorder | Olanzapine monotherapy is not indicated for major depressive disorder alone |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Olanzapine is a thienobenzodiazepine atypical antipsychotic with antagonist activity at dopamine D2, serotonin 5-HT2A, and multiple other receptors. Antipsychotic effect comes from dopamine and serotonin modulation, but nurses must remember olanzapine’s high metabolic liability—greater glucose elevation than some other atypicals in labeling comparisons—along with sedation and orthostatic hypotension.
Dosing overview
Verify every order against current prescribing information, age, and indication. Oral olanzapine is not indicated above 20 mg/day for schizophrenia or bipolar mania monotherapy.
Weight gain context (labeling): With median exposure ~6 weeks, adults gained a mean of 2.6 kg vs 0.3 kg loss on placebo; 22.2% gained ≥7% of baseline weight.
Missed dose: Take when remembered unless near next dose; do not double. Contact prescriber/pharmacy if multiple doses missed.
Before you give it — Safety check
Pretreatment checks
- Confirm indication is not dementia-related psychosis (boxed warning—increased mortality; not approved)
- Perform medication reconciliation for Symbyax components, benzodiazepines, and antidiabetic therapy
- Baseline weight; fasting glucose at baseline and periodically; plan lipid monitoring per protocol
- Assess fall risk, orthostatic vitals, and history of type 2 diabetes
Contraindications
- None listed for olanzapine monotherapy except hypersensitivity to olanzapine
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Fluoxetine (Symbyax) | Fixed combination for bipolar depression/TRD—monitor suicidality per Symbyax labeling | Verify correct product on MAR; do not give olanzapine alone when Symbyax is ordered |
| Risperidone and other antipsychotics | Additive sedation, EPS, and metabolic risk if duplicated | Reconcile antipsychotic orders; avoid unintended dual therapy |
| Antidiabetic agents | Olanzapine may worsen glucose control | Trend glucose; notify prescriber when fasting glucose rises on therapy |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Oral tablets: May be given without regard to meals per labeling.
- Zyprexa Zydis (ODT): Peel blister, place on tongue to dissolve; swallow with or without liquid; handle with dry hands
- Do not substitute olanzapine monotherapy when Symbyax (olanzapine + fluoxetine) is prescribed
Expected therapeutic response
- Gradual improvement in psychosis or mania over days to weeks
- Stable mental status without escalating metabolic symptoms
- Weight and glucose trends documented—early gain or hyperglycemia may appear before psychiatric stability is judged successful
Red flags — Stop and act
Escalate immediately for metabolic decompensation, NMS, or cerebrovascular events in vulnerable patients.
- Hyperglycemia: polydipsia, polyuria, weakness, or marked fasting glucose rise—hold and notify prescriber; consider diabetic ketoacidosis pathway per protocol
- Rapid weight gain: especially ≥7% baseline weight or belt-size change within weeks of starting therapy
- NMS: fever, rigidity, confusion, tachycardia, labile blood pressure—hold antipsychotic and activate emergency pathway
- New severe agitation with autonomic instability—differentiate NMS from psychiatric agitation
- Signs of cerebrovascular events in elderly (e.g., stroke)—labeling reports increased events in dementia-related psychosis trials
Adverse effects
| Adverse effect | Frequency / context | Nursing response |
|---|---|---|
| Weight gain | Mean +2.6 kg vs placebo over ~6 weeks; 22.2% gained ≥7% baseline weight | Weigh consistently; teach appetite changes; escalate metabolic plan |
| Hyperglycemia / dyslipidemia | Class effect; olanzapine has strong glucose association in labeling | Fasting glucose baseline and periodic; BMP and lipids per protocol when ordered |
| Somnolence / sedation | Common—especially early therapy | Fall precautions; differentiate sedation from NMS |
| Orthostatic hypotension | Can occur during titration | Orthostatic vitals; fall risk assessment |
| EPS / NMS | Less prominent than some agents but still possible | Monitor rigidity, fever, confusion; hold and escalate for NMS |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Prescribing information states no specific antidote for olanzapine overdose. Management is supportive: airway, breathing, circulation, cardiac monitoring, and treatment of agitation, hypotension, or NMS per protocol.
Contact local poison control or medical toxicology services per facility protocol and local emergency guidance for suspected overdose—especially with co-ingestants or altered mental status.
Look-alike / sound-alike and error prevention
- Olanzapine vs quetiapine vs risperidone—verify generic name; metabolic and sedation profiles differ
- Olanzapine vs olanzapine/fluoxetine (Symbyax)—never substitute monotherapy for combination product
- Multiple tablet strengths—independent double-check when 2.5, 5, 7.5, 10, 15, and 20 mg tablets are stocked
- ODT vs standard tablet—confirm formulation on MAR
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Metabolic screen | Weigh same scale/time; trend fasting glucose; teach polydipsia/polyuria |
| Food timing | May give without regard to meals |
| Commonly missed | Attributing thirst and weight gain to psychiatric improvement alone |
| Ask pharmacy when | Symbyax vs monotherapy questions, or glucose rise after initiation |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Elderly with dementia-related psychosis | Not approved; boxed warning of increased mortality |
| Diabetes / metabolic syndrome | High risk for worsening glucose and lipids—intensify monitoring |
| Adolescents | May experience greater weight gain; use labeled pediatric dosing |
| Pregnancy | Third-trimester exposure may cause neonatal extrapyramidal and/or withdrawal symptoms (agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorder)—monitor neonates and manage per protocol; consult specialist for risk/benefit because untreated schizophrenia or bipolar I disorder also carries maternal/fetal risk |
| Lactation | Olanzapine is present in human milk; reports describe excess sedation, irritability, poor feeding, and extrapyramidal symptoms in breastfed infants—balance breastfeeding benefits against clinical need and infant monitoring; effects on milk production are not specified in the reviewed prescribing information |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
- Fasting glucose at baseline and periodically; blood glucose monitoring per protocol
- Weight/BMI each visit or per unit metabolic protocol
- Lipid panel and basic metabolic panel when ordered
- Orthostatic vitals during titration; fall precautions
Patient teaching
- Report increased thirst, urination, hunger, or unexplained weight gain early
- Attend scheduled lab and weight checks—metabolic harm can occur before psychiatric symptoms improve
- Report fever, stiff muscles, confusion, or fast heartbeat immediately
- Rise slowly to prevent dizziness; avoid driving if excessively sedated
The Hold Rule
- Known hypersensitivity to olanzapine
- Suspected NMS or severe hyperglycemia/diabetic ketoacidosis
- Orders above 20 mg/day oral monotherapy without documented rationale
- Symptomatic orthostatic hypotension or syncope
- Dementia-related psychosis without specialist-documented exceptional plan
Clinical practice integration and workflow
Build metabolic surveillance into every olanzapine start and titration—weight and fasting glucose are as important as psychiatric symptom charts on inpatient behavioral health units.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, time—and right formulation (tablet vs ODT vs Symbyax)
- Review latest weight and fasting glucose before administration when on metabolic monitoring
- Confirm order does not exceed 20 mg/day monotherapy without rationale
2. High-alert and safety badge
Not universally high-alert, but carries boxed warning and major metabolic risk3. Clinical workflow: hold and question rules
- If fasting glucose jumps or patient reports polydipsia/polyuria, hold and notify prescriber/pharmacist
- If fever and rigidity appear, hold antipsychotic and initiate NMS pathway
4. Critical teach-back questions
- “What symptoms should you report right away?” (Thirst, frequent urination, weight gain, fever with stiff muscles.)
5. Care coordination
Pharmacist: Symbyax vs monotherapy verification, metabolic monitoring intervals, interaction checks
Prescriber / psychiatry: Glucose management, alternative antipsychotic selection when metabolic risk dominates
🧠 Quick mental checklist
- When was the last weight and fasting glucose—and are they trending the wrong direction?
- Is the patient on monotherapy or Symbyax—and does the MAR match?
- Any fever, rigidity, or confusion suggesting NMS rather than metabolic symptoms alone?
- Is this order above 20 mg/day without documented rationale?
- Is the indication dementia-related psychosis (not approved)?
Olanzapine NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for olanzapine using a tabbed case (MAR, labs, I&O, nursing notes), then priority action, cue recognition, trend interpretation, documentation cloze, NMS versus metabolic differentiation, and matrix urgency for hyperglycemia and weight gain—recognize cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, I&O, and nursing note details for this case.
- Olanzapine 15 mg PO at bedtime — started 10 days ago for bipolar mania
- Metformin 500 mg PO BID — home medication continued
- No PRN antipsychotic in last 24 h
- Next olanzapine dose due 2100
- Admission (day 1): fasting glucose 102 mg/dL; weight 78 kg
- Day 7: fasting glucose 156 mg/dL
- Today (day 10): fasting glucose 218 mg/dL; repeat BMP ordered
- Lipids: triglycerides 198 mg/dL (baseline 142); total cholesterol 212 mg/dL
- CK 165 U/L (within reference)
- Weight day 1: 78 kg; today: 81.4 kg (+3.4 kg in 10 days)
- Oral intake documented as increased snacking; fluids ~2.5 L/24 h
- Urine output adequate; no documented dehydration
- 42-year-old with bipolar mania; calmer affect but reports increased thirst and hunger
- Patient states belt is tighter; denies abdominal pain; mood stable; no suicidal ideation
- Separate drill note (matrix): T 39.4 °C, rigidity, confusion, HR 128, diaphoresis after olanzapine
Answer key & rationale
Frequently asked questions
What metabolic labs should nurses track on olanzapine?
Obtain fasting blood glucose at baseline and periodically during therapy per labeling. Monitor weight and BMI regularly because olanzapine commonly causes weight gain—in adult short-term trials patients gained a mean of 2.6 kg versus 0.3 kg loss on placebo, and 22.2% gained at least 7% of baseline weight. Order lipid panels per protocol; labeling reports dyslipidemia and sometimes very high triglycerides. Screen for polydipsia, polyuria, polyphagia, and weakness that may signal hyperglycemia or diabetic ketoacidosis.
When should a nurse hold olanzapine?
Hold for suspected neuroleptic malignant syndrome, severe hypersensitivity, symptomatic hyperglycemia or diabetic ketoacidosis pending prescriber review, orders above 20 mg/day oral monotherapy without documented rationale, or new severe orthostatic hypotension or syncope. Do not administer for dementia-related psychosis unless a specialist documents an exceptional plan—olanzapine is not approved for that use and carries a boxed warning of increased mortality.
Why is weight gain such a concern with olanzapine compared with other antipsychotics?
Prescribing information states olanzapine appears to have a greater association with glucose elevation than some other atypical antipsychotics and shows substantial weight gain in trials. With median exposure about 6 weeks, adults gained a mean 2.6 kg and long-term exposure averaged 5.6 kg; adolescents can gain more. Nurses should weigh patients on a consistent schedule, teach patients to report rapid weight or appetite changes, and escalate when gain threatens diabetes or cardiovascular risk.
Is there a specific antidote for olanzapine overdose?
No. Prescribing information states there is no specific antidote. Management is supportive: airway, breathing, circulation, continuous cardiac monitoring for arrhythmias, and treatment of extrapyramidal symptoms or NMS per protocol. Consider multiple drug involvement. Contact local poison control or medical toxicology services per facility protocol—not country-specific hotlines in patient-facing copy.
Can olanzapine be used for dementia-related psychosis?
No. Olanzapine carries a boxed warning that elderly patients with dementia-related psychosis treated with antipsychotic drugs have increased mortality, and olanzapine is not approved for dementia-related psychosis. If used off-label, monitor for somnolence, dysphagia, aspiration, and cerebrovascular events per labeling.
References
-
U.S. National Library of Medicine. OLANZAPINE tablet — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1ece23ae-2d4b-d6d7-e063-6394a90ac3b1
-
U.S. National Library of Medicine. Medication Guide: Olanzapine. DailyMed.https://dailymed.nlm.nih.gov/dailymed/medguide.cfm?setid=1ece23ae-2d4b-d6d7-e063-6394a90ac3b1
-
National Library of Medicine. MedlinePlus: Olanzapine.https://medlineplus.gov/druginfo/meds/a601213.html
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.